Observational studyBMC neurology2026
Optimal hematoma volume cutoffs and efficacy of minimally invasive surgery for thalamic hemorrhage: a propensity score-matched analysis.
Observational study in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05548530 (Analysis of Related Factors of Hematoma Morphology in Patients With Cerebral Hemorrhage and Prognosis Analysis of Different Regimens for Cerebral Hemorrhage), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Analysis of Related Factors of Hematoma Morphology in Patients With Cerebral Hemorrhage and Prognosis Analysis of Different Regimens for Cerebral Hemorrhage
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSpontaneous thalamic hemorrhage (TH) is associated with substantial morbidity and mortality. The optimal hematoma volume (HV) thresholds for prognostic stratification and the comparative effectiveness of minimally invasive surgery (MIS) versus conservative treatment remain uncertain.
methodsWe retrospectively analyzed consecutive patients with spontaneous TH admitted to a comprehensive stroke center n = 436 using a two-stage design. Stage 1: In the conservatively treated cohort n = 280, predictors of poor 90-day functional outcome (modified Rankin Scale [mRS] 3–6) were identified using multivariable logistic regression; a prognostic nomogram was constructed and validated. Receiver operating characteristic (ROC) analyses were used to determine HV cutoffs for predicting poor functional outcome and mortality. Stage 2: Patients with HV ≥ 7 mL were included in a comparative effectiveness analysis of MIS versus conservative treatment n = 208. Propensity score matching (PSM) was performed (1:1 nearest-neighbor without replacement; caliper = 0.2 SD of the logit of the propensity score) to balance baseline covariates, including age, sex, systolic blood pressure (SBP), Glasgow Coma Scale (GCS), National Institutes of Health Stroke Scale (NIHSS), intraventricular hemorrhage (IVH), Graeb score, and HV.
resultsIn conservatively treated patients n = 280, older age, higher SBP, and larger HV were independently associated with increased odds of poor 90-day outcome, whereas higher GCS was protective. The nomogram demonstrated good performance. ROC analyses identified 7 mL as the optimal HV cutoff for predicting poor functional outcome AUC = 0.86, and 13 mL for predicting mortality AUC = 0.81. After PSM in patients with HV ≥ 7 mL (n = 102; 51 matched pairs), MIS was associated with lower 90-day mortality compared with conservative treatment 9.8% vs. 29.4%, P = 0.01. However, the rate of functional independence did not differ significantly between groups 31.4% vs. 33.3%, P = 0.83.
conclusionHV is a key prognostic marker in TH, with 7 mL and 13 mL serving as clinically relevant thresholds for functional impairment and mortality, respectively. Among patients with HV ≥ 7 mL, MIS was associated with reduced 90-day mortality but not improved functional independence compared with conservative treatment.
trial registrationThis study adheres to the principles of the Declaration of Helsinki and is retrospectively registered in ClinicalTrials.gov (No. NCT05548530),Registration Date:08/31/2022.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.